Future Planet Capital

Ikarovec is a gene therapy company focused on developing early-stage assets for the treatment of common eye diseases, particularly diabetic macular edema. The company aims to address multiple disease targets and pathways, including dry-form age-related macular degeneration, neovascular (wet-form) age-related macular degeneration, and ocular hypertension. By targeting these conditions, Ikarovec seeks to provide effective treatments that restore sight and prevent blindness in patients.

Pencil Biosciences is focused on creating an innovative genome modulation platform that addresses the limitations of existing gene-editing technologies. By developing a programmable tool for genome modulation, the company aims to provide new therapeutic options for patients suffering from rare diseases. This technology is designed to have a broad impact, allowing medical professionals to navigate the complexities of gene editing more effectively. Through its advancements, Pencil Biosciences seeks to enhance the capabilities of gene-editing applications in the medical field.

CHAIN Biotechnology is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases. CHAIN is developing several therapeutic compounds targeted to the gut microbiome in the large intestine that can be delivered by our CADD technology.

Roslin Technologies is an ag-tech and food tech company focused on advancing biotechnologies to enhance protein production. The company specializes in animal stem cells, having developed perpetually self-renewing, pluripotent stem cells that have the potential to revolutionize the cultivated meat market. By providing these innovative cell lines and associated media formulations, Roslin Technologies enables companies in the cultivated meat industry to reduce costs and accelerate their market entry. Additionally, the company leverages its expertise in genomic capabilities to explore cell therapies aimed at treating incurable diseases in animals. Through these efforts, Roslin Technologies is committed to transforming the future of protein production.

Roslin Technologies is an ag-tech and food tech company focused on advancing biotechnologies to enhance protein production. The company specializes in animal stem cells, having developed perpetually self-renewing, pluripotent stem cells that have the potential to revolutionize the cultivated meat market. By providing these innovative cell lines and associated media formulations, Roslin Technologies enables companies in the cultivated meat industry to reduce costs and accelerate their market entry. Additionally, the company leverages its expertise in genomic capabilities to explore cell therapies aimed at treating incurable diseases in animals. Through these efforts, Roslin Technologies is committed to transforming the future of protein production.

Pencil Biosciences is focused on creating an innovative genome modulation platform that addresses the limitations of existing gene-editing technologies. By developing a programmable tool for genome modulation, the company aims to provide new therapeutic options for patients suffering from rare diseases. This technology is designed to have a broad impact, allowing medical professionals to navigate the complexities of gene editing more effectively. Through its advancements, Pencil Biosciences seeks to enhance the capabilities of gene-editing applications in the medical field.

Congenica is a biotechnology company based in Cambridge, Cambridgeshire, that specializes in clinical genomics. Founded in 2013, it offers a diagnostic decision support platform known as Sapientia, which integrates human DNA sequences with comprehensive clinical phenotyping. This platform enables clinicians to interpret genetic diseases more effectively by identifying mutations and filtering clinically relevant variants. By facilitating personalized medicine approaches, Congenica supports both clinicians and researchers in advancing patient care and research in the field of genetic diseases.

Tropic Biosciences specializes in developing high-performing commercial varieties of tropical crops, utilizing advanced non-GMO gene editing techniques. The company focuses on promoting cultivation efficiencies to address the increasing global food demand while enhancing grower wellbeing and consumer health. By significantly accelerating the breeding process, Tropic Biosciences aims to deliver genetic improvements that empower local farming communities to produce organic crops. Their commitment to sustainable agricultural practices reflects a broader goal of improving environmental outcomes.

Ikarovec is a gene therapy company focused on developing early-stage assets for the treatment of common eye diseases, particularly diabetic macular edema. The company aims to address multiple disease targets and pathways, including dry-form age-related macular degeneration, neovascular (wet-form) age-related macular degeneration, and ocular hypertension. By targeting these conditions, Ikarovec seeks to provide effective treatments that restore sight and prevent blindness in patients.

Pencil Biosciences is focused on creating an innovative genome modulation platform that addresses the limitations of existing gene-editing technologies. By developing a programmable tool for genome modulation, the company aims to provide new therapeutic options for patients suffering from rare diseases. This technology is designed to have a broad impact, allowing medical professionals to navigate the complexities of gene editing more effectively. Through its advancements, Pencil Biosciences seeks to enhance the capabilities of gene-editing applications in the medical field.

CHAIN Biotechnology is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases. CHAIN is developing several therapeutic compounds targeted to the gut microbiome in the large intestine that can be delivered by our CADD technology.

Resurgo Genetics is building a universal tool to precisely change any living system. We have identified a connectionist network core to life’s processes within every cell of all living things, and designed a generic tool to change it.

Roslin Technologies is an ag-tech and food tech company focused on advancing biotechnologies to enhance protein production. The company specializes in animal stem cells, having developed perpetually self-renewing, pluripotent stem cells that have the potential to revolutionize the cultivated meat market. By providing these innovative cell lines and associated media formulations, Roslin Technologies enables companies in the cultivated meat industry to reduce costs and accelerate their market entry. Additionally, the company leverages its expertise in genomic capabilities to explore cell therapies aimed at treating incurable diseases in animals. Through these efforts, Roslin Technologies is committed to transforming the future of protein production.

Congenica is a biotechnology company based in Cambridge, Cambridgeshire, that specializes in clinical genomics. Founded in 2013, it offers a diagnostic decision support platform known as Sapientia, which integrates human DNA sequences with comprehensive clinical phenotyping. This platform enables clinicians to interpret genetic diseases more effectively by identifying mutations and filtering clinically relevant variants. By facilitating personalized medicine approaches, Congenica supports both clinicians and researchers in advancing patient care and research in the field of genetic diseases.

Resurgo Genetics is building a universal tool to precisely change any living system. We have identified a connectionist network core to life’s processes within every cell of all living things, and designed a generic tool to change it.

CHAIN Biotechnology is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases. CHAIN is developing several therapeutic compounds targeted to the gut microbiome in the large intestine that can be delivered by our CADD technology.

Tropic Biosciences specializes in developing high-performing commercial varieties of tropical crops, utilizing advanced non-GMO gene editing techniques. The company focuses on promoting cultivation efficiencies to address the increasing global food demand while enhancing grower wellbeing and consumer health. By significantly accelerating the breeding process, Tropic Biosciences aims to deliver genetic improvements that empower local farming communities to produce organic crops. Their commitment to sustainable agricultural practices reflects a broader goal of improving environmental outcomes.

Quethera Limited is a gene therapy company based in Canterbury, United Kingdom, founded in 2013. The company specializes in developing innovative treatments for glaucoma and other ophthalmic diseases, particularly aimed at reducing progressive visual loss associated with these conditions. Quethera collaborates with leading experts in the field of glaucoma to design and conduct clinical trials that evaluate the efficacy and safety of its novel therapies, especially for patients who experience accelerated visual field loss. With a strong foundation in gene therapeutic design and development, Quethera is advancing its research pipeline from preclinical testing into clinical development, striving to enhance treatment options for patients suffering from common blinding eye diseases. As of August 2018, Quethera operates as a subsidiary of Astellas Pharma Inc.

CHAIN Biotechnology is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases. CHAIN is developing several therapeutic compounds targeted to the gut microbiome in the large intestine that can be delivered by our CADD technology.

Quethera Limited is a gene therapy company based in Canterbury, United Kingdom, founded in 2013. The company specializes in developing innovative treatments for glaucoma and other ophthalmic diseases, particularly aimed at reducing progressive visual loss associated with these conditions. Quethera collaborates with leading experts in the field of glaucoma to design and conduct clinical trials that evaluate the efficacy and safety of its novel therapies, especially for patients who experience accelerated visual field loss. With a strong foundation in gene therapeutic design and development, Quethera is advancing its research pipeline from preclinical testing into clinical development, striving to enhance treatment options for patients suffering from common blinding eye diseases. As of August 2018, Quethera operates as a subsidiary of Astellas Pharma Inc.

Cytox Limited specializes in developing products and services aimed at diagnosing and treating neurodegenerative disorders, particularly Alzheimer's disease. The company has created a genetic-based blood test that assesses the risk and diagnosis of Alzheimer's in its early stages, addressing a critical need as the prevalence of the disease rises globally. Cytox's offerings include cellular and genetic assays for identifying cell cycle deficits in patients, along with biomarker and drug-screening services for pharmaceutical companies engaged in clinical trials. The company collaborates with Affymetrix, part of Thermo Fisher Scientific, to enhance its commercial testing capabilities. Founded in 2004 and headquartered in Birmingham, United Kingdom, with additional offices in Manchester and Oxford, Cytox serves pharmaceutical and biotechnology firms, as well as research laboratories involved in clinical research and drug development.

Tropic Biosciences specializes in developing high-performing commercial varieties of tropical crops, utilizing advanced non-GMO gene editing techniques. The company focuses on promoting cultivation efficiencies to address the increasing global food demand while enhancing grower wellbeing and consumer health. By significantly accelerating the breeding process, Tropic Biosciences aims to deliver genetic improvements that empower local farming communities to produce organic crops. Their commitment to sustainable agricultural practices reflects a broader goal of improving environmental outcomes.

Congenica is a biotechnology company based in Cambridge, Cambridgeshire, that specializes in clinical genomics. Founded in 2013, it offers a diagnostic decision support platform known as Sapientia, which integrates human DNA sequences with comprehensive clinical phenotyping. This platform enables clinicians to interpret genetic diseases more effectively by identifying mutations and filtering clinically relevant variants. By facilitating personalized medicine approaches, Congenica supports both clinicians and researchers in advancing patient care and research in the field of genetic diseases.

Roslin Technologies is an ag-tech and food tech company focused on advancing biotechnologies to enhance protein production. The company specializes in animal stem cells, having developed perpetually self-renewing, pluripotent stem cells that have the potential to revolutionize the cultivated meat market. By providing these innovative cell lines and associated media formulations, Roslin Technologies enables companies in the cultivated meat industry to reduce costs and accelerate their market entry. Additionally, the company leverages its expertise in genomic capabilities to explore cell therapies aimed at treating incurable diseases in animals. Through these efforts, Roslin Technologies is committed to transforming the future of protein production.

Roslin Technologies is an ag-tech and food tech company focused on advancing biotechnologies to enhance protein production. The company specializes in animal stem cells, having developed perpetually self-renewing, pluripotent stem cells that have the potential to revolutionize the cultivated meat market. By providing these innovative cell lines and associated media formulations, Roslin Technologies enables companies in the cultivated meat industry to reduce costs and accelerate their market entry. Additionally, the company leverages its expertise in genomic capabilities to explore cell therapies aimed at treating incurable diseases in animals. Through these efforts, Roslin Technologies is committed to transforming the future of protein production.

Eagle Genomics is an enterprise software solutions company focused on managing and analyzing genomics and life sciences data. Its suite of products helps life science companies maximize the value of their research and development data by transforming data sets into actionable assets, thereby improving productivity and reducing costs and time in research processes. The company's platform offers an intuitive approach for curating, integrating, sharing, and analyzing scientific data, addressing the challenges faced by industries such as pharmaceuticals, consumer goods, and agri-tech. With a unique combination of expertise in biology, bioinformatics, data science, and software engineering, Eagle Genomics is well-positioned to tackle the complexities of data management in the genomics era, providing clarity on the value of digital assets and the return on information.

Quethera Limited is a gene therapy company based in Canterbury, United Kingdom, founded in 2013. The company specializes in developing innovative treatments for glaucoma and other ophthalmic diseases, particularly aimed at reducing progressive visual loss associated with these conditions. Quethera collaborates with leading experts in the field of glaucoma to design and conduct clinical trials that evaluate the efficacy and safety of its novel therapies, especially for patients who experience accelerated visual field loss. With a strong foundation in gene therapeutic design and development, Quethera is advancing its research pipeline from preclinical testing into clinical development, striving to enhance treatment options for patients suffering from common blinding eye diseases. As of August 2018, Quethera operates as a subsidiary of Astellas Pharma Inc.

Eagle Genomics is an enterprise software solutions company focused on managing and analyzing genomics and life sciences data. Its suite of products helps life science companies maximize the value of their research and development data by transforming data sets into actionable assets, thereby improving productivity and reducing costs and time in research processes. The company's platform offers an intuitive approach for curating, integrating, sharing, and analyzing scientific data, addressing the challenges faced by industries such as pharmaceuticals, consumer goods, and agri-tech. With a unique combination of expertise in biology, bioinformatics, data science, and software engineering, Eagle Genomics is well-positioned to tackle the complexities of data management in the genomics era, providing clarity on the value of digital assets and the return on information.

Cytox Limited specializes in developing products and services aimed at diagnosing and treating neurodegenerative disorders, particularly Alzheimer's disease. The company has created a genetic-based blood test that assesses the risk and diagnosis of Alzheimer's in its early stages, addressing a critical need as the prevalence of the disease rises globally. Cytox's offerings include cellular and genetic assays for identifying cell cycle deficits in patients, along with biomarker and drug-screening services for pharmaceutical companies engaged in clinical trials. The company collaborates with Affymetrix, part of Thermo Fisher Scientific, to enhance its commercial testing capabilities. Founded in 2004 and headquartered in Birmingham, United Kingdom, with additional offices in Manchester and Oxford, Cytox serves pharmaceutical and biotechnology firms, as well as research laboratories involved in clinical research and drug development.

CHAIN Biotechnology is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases. CHAIN is developing several therapeutic compounds targeted to the gut microbiome in the large intestine that can be delivered by our CADD technology.

Cytox Limited specializes in developing products and services aimed at diagnosing and treating neurodegenerative disorders, particularly Alzheimer's disease. The company has created a genetic-based blood test that assesses the risk and diagnosis of Alzheimer's in its early stages, addressing a critical need as the prevalence of the disease rises globally. Cytox's offerings include cellular and genetic assays for identifying cell cycle deficits in patients, along with biomarker and drug-screening services for pharmaceutical companies engaged in clinical trials. The company collaborates with Affymetrix, part of Thermo Fisher Scientific, to enhance its commercial testing capabilities. Founded in 2004 and headquartered in Birmingham, United Kingdom, with additional offices in Manchester and Oxford, Cytox serves pharmaceutical and biotechnology firms, as well as research laboratories involved in clinical research and drug development.

Eagle Genomics is an enterprise software solutions company focused on managing and analyzing genomics and life sciences data. Its suite of products helps life science companies maximize the value of their research and development data by transforming data sets into actionable assets, thereby improving productivity and reducing costs and time in research processes. The company's platform offers an intuitive approach for curating, integrating, sharing, and analyzing scientific data, addressing the challenges faced by industries such as pharmaceuticals, consumer goods, and agri-tech. With a unique combination of expertise in biology, bioinformatics, data science, and software engineering, Eagle Genomics is well-positioned to tackle the complexities of data management in the genomics era, providing clarity on the value of digital assets and the return on information.

Cytox Limited specializes in developing products and services aimed at diagnosing and treating neurodegenerative disorders, particularly Alzheimer's disease. The company has created a genetic-based blood test that assesses the risk and diagnosis of Alzheimer's in its early stages, addressing a critical need as the prevalence of the disease rises globally. Cytox's offerings include cellular and genetic assays for identifying cell cycle deficits in patients, along with biomarker and drug-screening services for pharmaceutical companies engaged in clinical trials. The company collaborates with Affymetrix, part of Thermo Fisher Scientific, to enhance its commercial testing capabilities. Founded in 2004 and headquartered in Birmingham, United Kingdom, with additional offices in Manchester and Oxford, Cytox serves pharmaceutical and biotechnology firms, as well as research laboratories involved in clinical research and drug development.